Patanol

Quick links to important sections

Patanol

Method of action: Antiallergic, Ophthalmologicals

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Patanol

What is Patanol? (Olopatadine Overview)

Property Description
Active ingredient Olopatadine hydrochloride
Form Ophthalmic solution (Eye drops), Nasal spray, Tablet
Pharmacological class Selective Histamine H1-Antagonist & Mast Cell Stabilizer
Common use Relief of symptoms associated with allergic conditions
Origin Synthetic (Tricyclic compound)

What is Olopatadine and How is it Classified?

Patanol is the trade name associated with the medicine whose active ingredient is the synthetic compound olopatadine hydrochloride. This molecule is structurally a tricyclic compound and is classified as a dual-action anti-allergic compound, functioning as both a selective Histamine H1-Receptor Antagonist and a Mast Cell Stabilizer. This classification means it directly intervenes in the allergic process by addressing the chemical messengers responsible for inflammation and irritation.

What Forms and General Purpose Does Patanol Serve?

The medication is most commonly known in its primary dosage form as a sterile ophthalmic solution (eye drops), where the olopatadine hydrochloride is suspended in an aqueous base vehicle for localized treatment. Olopatadine is a versatile single-ingredient product also prepared for other topical routes of administration, including a nasal spray, and is available as an oral tablet in certain regions. The general purpose of these formulations is to provide fundamental symptomatic relief by managing the body’s inflammatory response to allergens. Olopatadine is used for managing allergic conditions and is intended for easing allergy-related discomfort.

What Makes Patanol's Action Distinctive?

The distinctive nature of olopatadine stems from its two simultaneous actions to manage allergic symptoms. It effectively blocks the allergy messenger (histamine) already present in tissues, thereby reducing immediate irritation, and also works to stabilize the key cells (mast cells) to reduce the initial and continued release of histamine. This dual mechanism involves both H1-receptor antagonist and mast cell stabilizing properties. This combined approach provides a more comprehensive way to manage allergic reactions compared to medications that operate solely by blocking histamine.

Regulatory References

  1. Olopatadine Ophthalmic: MedlinePlus Drug Information

What side effects are possible with Patanol?

Patanol (olopatadine ophthalmic solution) safety profile is defined by official regulatory documentation, which classifies adverse reactions based on their frequency and the body system affected. These classifications distinguish between localized effects at the site of administration and non-ocular reactions resulting from systemic absorption.

Frequency and System-Organ Classes

The adverse reactions are categorized according to the frequency observed in clinical data, as reported in regulatory documents like the Summary of Product Characteristics (SmPC) and FDA labeling.

Classification Examples of Documented Adverse Reactions
Common Headache, nasopharyngitis, dysgeusia (taste distortion), dry eye, fatigue.
Uncommon Ocular burning or stinging, keratitis (corneal inflammation), eyelid swelling, dizziness.
Rare / Not Known Hypersensitivity reactions, somnolence (sleepiness), photophobia (light sensitivity), mydriasis (pupil dilation).

The official System-Organ Class (SOC) groupings show that the primary systems involved are Eye Disorders (e.g., ocular burning, dry eye) and Nervous System Disorders (e.g., headache, dysgeusia).

Serious Reactions and Safety Considerations

The regulatory profile documents potential, though rare, Hypersensitivity reactions, which are classified under Immune System Disorders.

Regarding Population-Specific Safety, the product’s safety and effectiveness have been established for use in pediatric patients two years of age and older. For reproductive safety, regulatory documents state that use during pregnancy should be avoided unless clearly necessary, and it is unknown if the substance passes into breast milk.

Safety-Related Constraints

A high-level safety constraint is noted regarding the potential for increased central nervous system (CNS) depression if olopatadine is used at the same time as other CNS depressants. Additionally, the presence of the preservative benzalkonium chloride (BAK) is noted as a potential source of eye irritation and corneal damage with prolonged use, requiring particular caution.

Overdose and Emergency Response

The official regulatory profile for Patanol (olopatadine ophthalmic solution) defines a clear approach to potential overdose, distinguishing between ocular exposure and accidental ingestion. Regulatory documents consistently state that no toxic effects are expected following an ocular overdose of the eye drops. Furthermore, no toxic effects are anticipated if the entire contents of a single container are accidentally swallowed. This assessment includes analysis for vulnerable populations, such as infants, confirming a significant safety margin relative to potential systemic effects, including concerns about cardiac repolarization.

Despite the low expected toxicity, official government guidance mandates a specific emergency response for ingestion. If the product is swallowed, immediate medical attention is required, and the patient must contact a Poison Control Center or seek medical help right away. This action is required to ensure professional evaluation and appropriate patient management following any systemic exposure.

Official prescribing information confirms that no specific antidote is known for olopatadine overdose. Therefore, management must focus on providing symptomatic and supportive treatment. Healthcare professionals are required to implement appropriate monitoring of the patient during the recovery phase, ensuring systematic management of any unexpected manifestations, adhering strictly to the official regulatory guidelines for overdose response.

Therapeutic Uses of Patanol

What Patanol Treats: Main Uses and Benefits

Patanol (olopatadine ophthalmic solution) is primarily indicated for the temporary management of ocular signs and symptoms related to allergic conjunctivitis. This condition involves an inflammatory response in the eye triggered by environmental factors such as pollen, pet dander, or grass. The administration of Patanol is intended to offer symptomatic relief when these allergens cause eye irritation.

The medication may be considered for addressing the common manifestations of this allergic response. These include ocular itching, which is often the most reported symptom, along with related redness and watering of the eyes. By helping to mitigate these acute effects, the medication supports patient comfort and may assist in maintaining daily functioning during exposure to allergens.


Quick Fact: Relief for Allergic Itching

Patanol is used to help manage the temporary, intense itching sensation in the eyes caused by seasonal or perennial allergic exposure.

Eligibility and Restrictions for Use

Who Can and Cannot Use Patanol?

The eligibility for Patanol (olopatadine ophthalmic solution) is strictly defined by regulatory authorities and is based on a patient’s age and specific clinical status. The medicine is classified for use under the following official population rules.


Contraindications and Age Limitations

Classification Population Status
Absolute Contraindication Patients with known hypersensitivity or allergy to olopatadine hydrochloride or any component of the eye drop formulation must not use the medicine.
Established Use Adults and pediatric patients 3 years of age and older are approved for use [FDA Drug Labeling].
Use Not Established Safety and effectiveness have not been established in pediatric patients below the age of 3 years [FDA Drug Labeling].

Special Population Restrictions

Population Group Regulatory Status
Pregnancy Not recommended for use unless deemed necessary by the prescriber, as risk cannot be excluded.
Lactation Use is not recommended due to potential risk to the newborn/infant.
Older Adults (Geriatric) No special restrictions or dosage adjustments are necessary.
Renal/Hepatic Impairment No dosage adjustment is expected to be necessary due to minimal systemic absorption [EMA Opatanol SmPC].

What should I know about interactions with other medicines?

Patanol (olopatadine) ophthalmic solution demonstrates a low potential for systemic drug interactions due to minimal systemic absorption. Plasma concentrations following ocular administration are generally below the level required to cause systemic effects. Regulatory documentation confirms that olopatadine is not an inhibitor of major cytochrome P-450 isozymes (e.g., CYP1A2, 2D6, 3A4), which indicates a low likelihood of metabolic interactions with co-administered medicines. Consequently, the systemic pharmacokinetic risk is considered negligible, and no dosage adjustment is expected to be necessary for the ophthalmic solution in patients with hepatic or renal impairment.

Administration Timing and Non-Ophthalmic Interactions

If Patanol eye drops are co-administered with any other topical ocular preparation, an interval of at least five minutes must be allowed between successive applications, as required by regulatory instructions. This rule ensures proper drug delivery and absorption. For the non-ophthalmic formulations of olopatadine, such as the nasal spray, the regulatory profile includes a specific pharmacodynamic warning. Co-administration of the nasal spray with Central Nervous System (CNS) depressants, including alcohol, must be avoided due to the documented risk of additive effects that may result in reduced alertness and impaired CNS performance.

Mechanism of Action

Patanol (olopatadine) functions through a dual pharmacodynamic mechanism, acting as both a selective mathrmH1-receptor antagonist and a mast cell stabilizer. Olopatadine exhibits competitive binding to the mathrmH1 histamine receptor. This interaction blocks the receptor site, preventing the subsequent binding of endogenous histamine and modulating the immediate physiological effects mediated by this receptor.

Simultaneously, olopatadine modulates intracellular processes within the mast cell. It directly influences and stabilizes the mast cell membrane potential, which inhibits the cascade leading to cell degranulation. By inhibiting this process, the release of key pro-inflammatory mediators into the surrounding tissue, specifically histamine, tryptase, and leukotrienes, is significantly reduced. The resultant modulation of the inflammatory response within the target tissue is achieved solely by interrupting these established biochemical pathways.

Dosage and Administration Information

How to Use Patanol (Olopatadine)

The administration of olopatadine is governed by the specific product form and concentration, dictating the approved route and dosing frequency. Olopatadine is primarily administered either topically in the eye as an ophthalmic solution or intranasally as a metered spray, though an oral tablet form is also approved in certain global regions.


Official Dosing and Frequency Patterns

The frequency of use for the ophthalmic solutions is concentration-dependent. The 0.1% strength is administered Twice Daily (BID), typically with doses separated by 6 to 8 hours. In contrast, the higher concentrations, 0.2% and 0.7%, are administered Once Daily (QD), with a standard dose of one drop into the affected eye(s). The intranasal spray formulation is administered Twice Daily (BID) at a dose of two sprays per nostril for adults and children 12 years and older.

Administration Requirements

Usage instructions include age-specific adjustments and critical procedural steps. For the nasal spray, a reduced dose of one spray per nostril is administered to children aged 6 to 11 years. The nasal device must also be primed prior to initial use and if unused for a specified period to ensure proper dosing. When administering the ophthalmic solution, soft contact lenses must be removed before application, with reinsertion required to wait at least 10 to 15 minutes. If using any other topical ophthalmic product, a minimum of five minutes must be allowed between the administration of olopatadine and the other medication.

Recent Clinical Evidence

Patanol (Olopatadine) Recent Clinical Evidence

Olopatadine, the active ingredient in Patanol, is a medication primarily used to address the symptoms of allergic conjunctivitis. Recent clinical research has continued to affirm the compound's established role as an H1-receptor antagonist and mast cell stabilizer in the management of ocular allergy.


Efficacy and Symptom Relief

Studies have focused on the compound's ability to provide rapid and sustained relief from common ocular allergy symptoms. Research evaluating symptom scores in participants with seasonal allergic conjunctivitis has generally demonstrated a significant difference compared to placebo. Key symptoms evaluated in these trials include ocular itching and redness (conjunctival hyperemia).

One area of ongoing investigation involves assessing the drug's effect when used prophylactically (before allergen exposure) versus reactively (at the onset of symptoms). Findings suggest that using the drug prior to expected allergen contact may provide enhanced protection against a subsequent allergic reaction, supporting its use as a preventive measure in predictable allergy seasons.


Tolerability and Safety Profile

Clinical trials consistently report that olopatadine ophthalmic solution is generally well tolerated. The most common adverse events documented are mild and transient, primarily involving local effects such as temporary burning or stinging upon administration, headache, and a sensation of dryness in the eye. The overall rate of discontinuation from clinical studies due to adverse events is reported as low, suggesting a favorable safety profile in the indicated patient population. Comparative studies against other topical antihistamines continue to be conducted to characterize its relative performance and safety metrics.

Key Studies & References

  1. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans
  2. PATANOL® 0.1% eye drops, solution (Summary of Product Characteristics/Datasheet)

Frequently Asked Questions (FAQ)

Common questions about Patanol (FAQ)

Q: How quickly can I expect Patanol to start working after the first application?

Studies and official information indicate that relief from symptoms generally begins quickly. Clinical studies showed the drug's anti-histaminic effects were measurable as soon as five minutes after application. This rapid action is part of the medication’s intended function to address the allergic response.

Q: Is Patanol intended for short-term use during allergy seasons or for daily, year-round use?

For patients with seasonal allergic conjunctivitis, regulatory guidance indicates that therapy is often maintained throughout the pollen season. Treatment may be continued for as long as necessary to sustain improvement in symptoms, as determined by the prescriber. The duration of use is ultimately determined by the prescribing health professional.

Q: Why do some people report a change in taste (dysgeusia) after using Patanol?

Dysgeusia, which is the official term for an unpleasant or unusual taste, is listed in regulatory documents as a common side effect. This change in taste is believed to occur because a portion of the eye drop solution drains from the eye into the throat through the nasolacrimal ducts.

Q: What should I watch for as a sign of a rare or serious allergic reaction to Patanol?

Official patient information states that signs of a rare, serious allergic reaction include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Furthermore, severe eye symptoms such as increased redness, swelling, or crusting are signals that may warrant consulting a health professional.

Q: How does Patanol compare in mechanism to other common over-the-counter allergy drops?

Patanol contains the active ingredient olopatadine, which functions as a dual-action agent. Regulatory documents state that this ingredient works simultaneously as a selective H1-antagonist (blocking histamine) and a mast cell stabilizer. This combined mechanism offers a comprehensive approach to managing allergic eye symptoms.

Q: Why must soft contact lenses be removed before applying Patanol?

Official administration requirements indicate that soft contact lenses are to be removed before application because the solution contains the preservative benzalkonium chloride (BAK). This preservative can be absorbed by soft lenses and may potentially cause discoloration or irritation. Administration requirements suggest waiting approximately 10 minutes before reinserting the lenses.

Q: Can Patanol affect my ability to drive or operate heavy machinery?

Olopatadine is known to potentially cause somnolence, or sleepiness, which can reduce mental alertness. Official labeling includes a caution regarding engaging in hazardous activities, such as driving or operating machinery, should the user experience this reduction in mental alertness.

Q: Are there any known interactions between Patanol and prescription medications for mental health or ADHD?

Official product information includes a warning that co-administration of olopatadine with Central Nervous System (CNS) depressants is to be avoided. This is because using both together may lead to additional reductions in alertness or impairment of CNS performance. This category includes alcohol and may include certain prescription medications.

Q: Is Patanol a treatment for all types of eye redness or irritation?

Regulatory documents specify that Patanol is indicated for the symptomatic management of ocular itching and redness associated with allergic conjunctivitis. The medication’s primary purpose is to manage symptoms resulting from an allergic response.

Q: How long does the effect of one drop of Patanol typically last?

The duration of the drug's effect depends on the concentration used. For the Patanol 0.1% strength, which is typically dosed twice daily, official information indicates it provides relief for up to 8 hours after administration.

Q: Is Patanol effective for eye symptoms caused by pet dander or mold?

Official Drug Facts labeling indicates the product is approved to temporarily relieve itchy eyes caused by common indoor and outdoor allergens. This includes allergens such as pollen, ragweed, grass, animal hair, and dander.

Q: Is it normal to feel like there is something in my eye after applying Patanol?

Official regulatory-linked patient information lists the sensation of having something in the eye, known as foreign body sensation, as a potential side effect. This sensation is usually described as mild and transient.

Q: Are there any specific concerns about Patanol use for people with dry nose or nasal conditions?

Regulatory guidance for olopatadine’s nasal formulation includes a caution against use in patients who have pre-existing nasal disease other than allergic rhinitis, or those with recent nasal surgery or injury. This information serves as a note of caution for patients with concurrent nasal conditions.

Q: What should a user do if they accidentally instill more than the recommended amount of Patanol?

Due to the ophthalmic solution's minimal systemic absorption, an overdose of the eye drops is not generally expected to be dangerous. However, official labeling states that in the event of an overdose, appropriate patient monitoring and management are indicated.

Q: What are the different strengths or concentrations of Patanol available?

The active ingredient olopatadine ophthalmic solution is available in several regulatory-approved concentrations. These strengths include 0.1% (the original Patanol concentration), 0.2%, and 0.7%.

Q: What are the risks if Patanol is accidentally swallowed?

Official patient information states that contacting a Poison Control Center or medical assistance right away is required if the solution is swallowed. Ingestion of large doses of H1 antihistamines can be associated with side effects such as cardiac arrhythmia, which requires monitoring.

Q: Why is Patanol often mentioned alongside Pataday and Pazeo?

Patanol, Pataday, and Pazeo are all trade names that share the same active ingredient, olopatadine, but are available in different concentrations. Patanol was the original brand name for the 0.1% concentration. The different names distinguish the available product strengths.

Q: What is the difference between Patanol and the generic olopatadine?

Patanol is the registered brand name for the 0.1% olopatadine ophthalmic solution. Olopatadine is the official generic name for the active drug substance itself, regardless of whether it is sold under a brand name or as a generic product.

How should Patanol be stored and disposed of?

Storage Requirements

Patanol (olopatadine ophthalmic solution) must be stored at a controlled room temperature, specifically between 4°C and 25°C (39°F and 77°F), and must be protected from freezing. To preserve the sterility of the drops, the bottle must be kept tightly closed when not in use, and the dropper tip must not touch any surface. The solution should not be used if it changes color or becomes cloudy.

Stability and Disposal

The product has a stability limit once opened; the solution must be discarded four weeks (28 days) after the date of first opening. For safety, the medicine must be stored out of the sight and reach of children. If the solution is swallowed, immediate medical assistance is required. Unused or expired medication must be disposed of according to local regulatory guidelines, and must not be poured down the sink or thrown into household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Patanol found in:

A-Z Index: